ScripProtagonist Therapeutics may be far behind several other companies developing next-generation obesity drugs, but the company thinks it can narrow the gap by focusing on the oral market. The company an
ScripBoth private and public biopharmaceutical companies are struggling to raise fresh capital for ongoing research and development programs, despite expectations earlier in 2025 that financial market con
ScripNovo Nordisk’s Wegovy (injectable semaglutide) has made its India debut, setting the stage for a tight battle with rival Eli Lilly’s Mounjaro (tirzepatide) in a market where an estimated 254 million p
ScripAmgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II t